Skip to main content

Insulet Corporation

corporate_fare Company Profile

Insulet Corporation

PODD·NASDAQ·Industrial Applications And Services·CIK 0001145197

Insulet Corporation develops, manufactures, and sells continuous insulin delivery systems for individuals with insulin-dependent diabetes. The company's Omnipod platform features three main products: the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the Classic Omnipod Insulin Management System. Beyond its diabetes care products, Insulet also produces pods for Amgen. These pods are integrated into Amgen's Neulasta Onpro kit, which is a delivery system for Amgen's Neulasta medication, designed to help reduce infection risk following intense chemotherapy. Diabetes is a chronic, life-threatening condition where the body cannot produce or effectively use insulin, leading to unregulated blood glucose levels. Both high blood glucose (hyperglycemia) and low blood glucose (hypoglycemia) can cause serious complications, including confusion, vomiting, dehydration, loss of consciousness, and long-term issues like blindness, kidney disease, nervous system disease, vascular diseases, stroke, cardiovascular disease, or death. Type 1 diabetes involves the body's near-complete inability to produce insulin, requiring daily insulin therapy for survival. Insulet estimates approximately 6 million people have type 1 diabetes in the countries it serves. Type 2 diabetes, the more common form, involves the body's inability to properly use or produce enough insulin, with increasing incidence in younger populations.

Insulet Corporation (NASDAQ:PODD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for PODD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Insulet Reports Strong Q4 & FY25 Results, Exceeds Guidance, and Boosts Share Buyback by $350M to $475M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.71B
Net Income
$247.1M
Diluted EPS
$3.48
Op. Cash Flow
$569.3M
Free Cash Flow
$377.7M
Gross Profit
$1.94B
Operating Income
$473.8M
Cash & Equivalents
$716.1M
Total Debt
$18.4M
Debt / Equity
0.01×
Net Margin
9.1%
Shares Outstanding
70.39M sh
Source: 10-K · filed 2026-02-18 · accession 0001145197-26-000028
$133.1 -0.05% today
52-week range · as of 2026-11-04 $126.4 – $354.88
Market cap
$9.24B
Volume
1.8M (1.2× avg)
3-mo avg 1.5M
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PODD - Filings & News (Page 2)

PODD
Feb 18, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $245.01
Real-time Price: $133.10 info
Change: -$111.91 (-46%) info
Market Cap: $9.238B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets